Findings are from the multicenter, prospective, Phase 3 STAMPEDE trial “Our findings suggest that the Decipher Prostate test may provide an important new tool to help guide treatment decisions for the ...
A new blended genome genetic test being studied in a major clinical trial may help identify men at highest risk of aggressive ...
TAMPA, Fla. (Dec. 19, 2025) — A new Moffitt Cancer Center study suggests a widely used genomic test can more accurately identify which men with early prostate cancer are at high risk for their disease ...
Findings from the first prospective validation trial for biomarker presented at ASTRO 2025 Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, announced that new data from the ...
Diagnostic tools based on artificial intelligence are now making their way into Norwegian hospitals. AI can independently read X-ray images and detect bone fractures, or assess cancer tumors in both ...
What actually happens in a prostate cancer screening? - A prostate screening test can help to detect early signs of prostate ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, and University College London (UCL) today announced that data published online in ...
Findings from the first prospective validation trial for biomarker presented at ASTRO 2025 SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (VCYT) (Nasdaq: VCYT), a leading genomic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results